Abstract
1. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007;297:471-9. 2. Brown JR, Birkmeyer NJ, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801-13. 3. Coleman CI, Rigali VT, Hammond J, Kluger J, Jeleniowski KW, White CM. Evaluating the safety implications of aprotinin use: The Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS). J Thorac Cardiovasc Surg. 2007;133:1547-52. 4. US Food and Drug Administration. Early communication about an ongoing safety review: aprotinin injection (marketed as Trasylol). Center for Drug Evaluation and Research website 2007 Oct 25 [cited 2007 Dec 6]. Available from: http://www.fda. gov/cder/drug/early_comm/aprotinin.htm 5. Skillington PD, Fuller JA, Grigg LE, Yapanis AG, Porter GF. Ross procedure. Inserting the autograft using a fully supported root replacement method; techniques and results. J Heart Valve Dis. 1999;8:593-600. 6. Punjabi PP, Wyse RKH, Taylor KM. Role of aprotinin in the management of patients during and after cardiac surgery. Exp Opin Pharmacother. 2000;1: 1353-65. Brief Clinical Reports
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Thoracic and Cardiovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
